Francesca Gay

17.9k total citations · 3 hit papers
183 papers, 5.1k citations indexed

About

Francesca Gay is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Francesca Gay has authored 183 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Hematology, 100 papers in Oncology and 95 papers in Molecular Biology. Recurrent topics in Francesca Gay's work include Multiple Myeloma Research and Treatments (147 papers), Protein Degradation and Inhibitors (73 papers) and Cancer Treatment and Pharmacology (51 papers). Francesca Gay is often cited by papers focused on Multiple Myeloma Research and Treatments (147 papers), Protein Degradation and Inhibitors (73 papers) and Cancer Treatment and Pharmacology (51 papers). Francesca Gay collaborates with scholars based in Italy, United States and Netherlands. Francesca Gay's co-authors include Mario Boccadoro, Pieter Sonneveld, María‐Victoria Mateos, Shaji Kumar, S. Vincent Rajkumar, Antonio Palumbo, Kenneth C. Anderson, Mark van Duin, Robert A. Kyle and Pellegrino Musto and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Francesca Gay

166 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiple myeloma

2017 755 citations Mark van Duin, Pieter Sonneveld et al. profile →
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

2017 392 citations Maria Teresa Petrucci, Paul G. Richardson et al. Journal of Clinical Oncology profile →
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

2023 77 citations Noopur Raje, Kenneth C. Anderson et al. Blood Cancer Journal profile →

Peers

Countries citing papers authored by Francesca Gay

Since Specialization

Citations

This map shows the geographic impact of Francesca Gay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesca Gay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesca Gay more than expected).

Fields of papers citing papers by Francesca Gay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesca Gay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesca Gay. The network helps show where Francesca Gay may publish in the future.

Co-authorship network of co-authors of Francesca Gay

This figure shows the co-authorship network connecting the top 25 collaborators of Francesca Gay. A scholar is included among the top collaborators of Francesca Gay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesca Gay. Francesca Gay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma 2025 ·Cancers ·Katia Mancuso, Simona Barbato, (unknown), Francesca Gay, Pellegrino Musto, Massimo Offidani, Maria Teresa Petrucci, Elena Zamagni, Renato Zambello, Michèle Cavo	0
2	Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies 2025 ·Annals of Hematology ·Luciano J. Costa, Francesca Gay, Ola Landgren, María‐Victoria Mateos, Philippe Moreau, Cyrille Touzeau, (unknown), (unknown), Rani Najdi, Katja Weisel	0
3	Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events 2025 ·American Journal of Hematology ·Evangelos Terpos, Suzanne Trudel, María‐Victoria Mateos, (unknown), (unknown), Meletios Α. Dimopoulos, Simona Degli Esposti, Asim V. Farooq, Maria Gavriatopoulou, Francesca Gay, Vânia Hungria, K. Martin Kortüm, Xavier Leleu, Sagar Lonial, Hang Quach, Lugui Qiu, Karthik Ramasamy, Kazuhito Suzuki, Katja Weisel, Paul G. Richardson	2
4	Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial. 2024 ·Journal of Clinical Oncology ·Paula Rodríguez‐Otero, Philippe Moreau, Meletios Α. Dimopoulos, Meral Beksaç, Aurore Perrot, Annemiek Broijl, Francesca Gay, Roberto Mina, Niels W.C.J. van de Donk, Fredrik Schjesvold, Michel Delforge, Hermann Einsele, Andrew Spencer, Sarah Lonergan, Diego Vieyra, Anna Sitthi-Amorn, Robin Carson, Joan Bladé, Mario Boccadoro, Pieter Sonneveld	9
5	Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry 2024 ·PLoS ONE ·(unknown), Dennis Petrie, Anthony Harris, Laura Fanning, Erica M. Wood, Elizabeth Moore, Cameron Wellard, (unknown), (unknown), Bradley Augustson, Gordon Cook, Francesca Gay, Georgia McCaughan, Peter Mollee, (unknown), Zoe McQuilten	0
6	Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment 2024 ·Cancers ·(unknown), (unknown), (unknown), (unknown), (unknown), Fabrizio Vallelonga, Dario Leone, (unknown), (unknown), Sara Bringhen, Francesca Gay, Gianni Pedrizzetti, Franco Veglio, Alberto Milan	0
7	Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel breakdown → 2023 ·Blood Cancer Journal ·Noopur Raje, Kenneth C. Anderson, Hermann Einsele, Yvonne A. Efebera, Francesca Gay, Sarah P. Hammond, Alexander M. Lesokhin, Sagar Lonial, Heinz Ludwig, Philippe Moreau, Krina K. Patel, Karthik Ramasamy, María‐Victoria Mateos	77
8	Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study 2023 ·Cancers ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Dario Leone, Francesca Gay, Sara Bringhen, Franco Veglio, Alberto Milan, Fabrizio Vallelonga	4
9	Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience 2023 ·Cancers ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Dario Leone, Fabrizio Vallelonga, Sara Bringhen, Francesca Gay, Franco Veglio, Alberto Milan	2
10	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile 2022 ·Journal of Clinical Oncology ·Davine Hofste op Bruinink, Rowan Kuiper, Mark van Duin, Tom Cupedo, Vincent H. J. van der Velden, Remco M. Hoogenboezem, Bronno van der Holt, H. Berna Beverloo, (unknown), (unknown), Francesca Gay, Annemiek Broijl, Hervé Avet‐Loiseau, Nikhil C. Munshi, Pellegrino Musto, Philippe Moreau, Sonja Zweegman, Niels W.C.J. van de Donk, Pieter Sonneveld	16
11	MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials 2022 ·Blood ·Bruno Paiva, Irene Manrique, Meletios Α. Dimopoulos, Francesca Gay, Chang‐Ki Min, Sonja Zweegman, Ivan Špıčka, Raphael Teipel, María‐Victoria Mateos, Nicola Giuliani, Michèle Cavo, (unknown), Weijun Fu, Kaveri Suryanarayan, Alexander Vorog, Cong Li, Bingxia Wang, Jose Estevam, Richard Labotka, Ajeeta B. Dash	25
12	The role of autologous stem-cell transplantation in multiple myeloma in 2021 2021 ·Current Opinion in Oncology ·Roberto Mina, Francesca Gay	3
13	MRD Assessment in Multiple Myeloma: Progress and Challenges 2021 ·Current Hematologic Malignancy Reports ·Luca Bertamini, Mattia D’Agostino, Francesca Gay	35
14	Antibody-drug conjugates: when chemotherapy meets immuno-oncology 2021 ·The Lancet Haematology ·Roberto Mina, Francesca Gay	1
15	Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction 2021 ·Cancers ·(unknown), (unknown), (unknown), Fabrizio Vallelonga, Michele Covella, (unknown), (unknown), (unknown), Dario Leone, (unknown), (unknown), Marco Salvini, Francesca Gay, Sara Bringhen, Franco Rabbia, Franco Veglio, Alberto Milan	11
16	Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing 2020 ·Clinical Cancer Research ·Mattia D’Agostino, Gian Maria Zaccaria, Bachisio Ziccheddu, Even H. Rustad, Elisa Genuardi, Andréa Capra, Stefania Oliva, Daniel Auclair, (unknown), Paola Colucci, Jonathan J. Keats, Manuela Gambella, Sara Bringhen, Alessandra Larocca, Mario Boccadoro, Niccolò Bolli, Francesco Maura, Francesca Gay	38
17	Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma 2019 ·Cancers ·Francesca Bonello, Roberto Mina, Mario Boccadoro, Francesca Gay	38
18	Special problems in the management of elderly patients with multiple myeloma 2018 ·European Journal of Internal Medicine ·Francesca Gay, Alessandra Larocca	1
19	CD38 as an immunotherapeutic target in multiple myeloma 2018 ·Expert Opinion on Biological Therapy ·Francesca Bonello, Mattia D’Agostino, (unknown), Chiara Cerrato, Mario Boccadoro, Francesca Gay	30
20	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial 2008 ·Blood ·Antonio Palumbo, Sara Bringhen, Anna Marina Liberati, Tommaso Caravita, Antonietta Falcone, Vincenzo Callea, Marco Montanaro, Roberto Ria, Antonio Capaldi, Renato Zambello, Giulia Benevolo, Daniele Derudas, Sylvain Doré, Federica Cavallo, Francesca Gay, Patrizia Falco, Giovannino Ciccone, Pellegrino Musto, Michèle Cavo, Mario Boccadoro	250

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact